ro-13-6298 and Mycosis-Fungoides

Mycosis fungoides is a neoplasia immunologically defined as a cutaneous T cell lymphoma. It is an uncommon, chronic, and usually fatal disease that runs a progressive multistaged course. The present study describes a case of mycosis fungoides, limited to the skin, which was successfully controlled with the arotinoid Ro 13-6298. Review of the role of retinoids in dermatology and oncology is presented with a special emphasis on the arotinoid.

Topics: Antineoplastic Agents; Benzoates; Drug Therapy, Combination; Etretinate; Female; Humans; Lymphoma; Middle Aged; Mycosis Fungoides; PUVA Therapy; Retinoids; Skin Neoplasms; T-Lymphocytes

Topics: Acne Vulgaris; Benzoates; Etretinate; Half-Life; Humans; Mycosis Fungoides; Psoriasis; PUVA Therapy; Retinoids

Five patients with T-cell lymphoma of the skin (mycosis fungoides; Sézary syndrome) were given parenterally arotinoid ethyl ester (Ro 13-6298) at a daily dose of 0.5-4.0 micrograms/kg body weight, to a total dose of 20 mg over maximally 31 weeks. In three patients, among them one with tumourous mycosis fungoides, there was complete regression of the cutaneous lesions. In another patient the cutaneous changes, some of them with ulceration, regressed so that there were only residual infiltrates. In the case of the Sézary syndrome there was no response. Most important side-effects of treatment were cheilitis, moist and sticky skin, paronychia and dry mucosae. The most serious side-effect was pain in muscles, joints and bones. There were no significant changes in biochemical values during the treatment.

Topics: Adult; Aged; Alopecia; Benzoates; Female; Humans; Lymphoma; Male; Middle Aged; Mycosis Fungoides; Pain; Retinoids; Sezary Syndrome; Skin Neoplasms; T-Lymphocytes